Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

2(50.0%)

4Total

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06175338Phase 1Active Not Recruiting

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Role: lead

NCT05825781Phase 1Active Not Recruiting

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Role: lead

NCT05654454Phase 3Recruiting

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Role: lead

NCT06005532Phase 3Unknown

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Role: lead

All 4 trials loaded